Clinical Trial WatchDeveloping
Five-Year Duchenne Cell Therapy Data Put Time at the Center
Capricor's deramiocel update is a Duchenne time-preservation story, but company-reported long-term data need careful caveats.
Why now
This is much stronger than a generic DMD update because two clocks are now running: Capricor announced five-year HOPE-2 open-label extension data for deramiocel and, separately, an FDA advisory committee meeting was scheduled for July 29 with an August 22 PDUFA target date. That gives VV a clear 'watch before the regulator decides' moment. The human frame is preservation of time in a progressive disease, but the source is company-reported and must be caveated.
- Overclaim risk
- high
- Primary source
- Company
- Published
- Jun 28, 2026